Company intelligence / Profile preview

Baiaotai

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Baiaotai’s key program BAT2206 (ustekinumab biosimilar) has advanced to out-licensing for EU, UK, Switzerland, and Australia, likely indicating successful Phase 3 and regulatory submission/commercialization readiness.

Therapeutic areas: Immunology
Modalities: Monoclonal antibodyBiologicBiosimilar
Industry: Biotech

Partnerships

Gedeon Richter Plc.

Beyond the preview

Go deeper on Baiaotai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Baiaotai.

Explore the full profile